Platelet receptors as therapeutic targets: Past, present and future

被引：63

作者：

Jamasbi, Janina ^{[1
]}

Ayabe, Keng ^{[2
]}

Goto, Shinya ^{[2
]}

Nieswandt, Bernhard ^{[3
,4
]}

Peter, Karlheinz ^{[5
]}

Siess, Wolfgang ^{[1
,6
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Inst Prevent Cardiovasc Dis, Munich, Germany

[2] Tokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa, Japan

[3] Univ Wurzburg, Univ Hosp, Expt Biomed, Wurzburg, Germany

[4] Univ Wurzburg, Rudolf Virchow Ctr, Wurzburg, Germany

[5] Baker IDI Heart & Diabet Inst, Atherothrombosis & Vasc Biol, Melbourne, Vic, Australia

[6] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany

来源：

THROMBOSIS AND HAEMOSTASIS | 2017年 / 117卷 / 07期

基金：

英国医学研究理事会;

关键词：

Antiplatelet agents; GP Ib alpha; GP VI; GP IIb/IIIa; PAR-1; VON-WILLEBRAND-FACTOR; ACUTE CORONARY SYNDROMES; INDUCED THROMBUS FORMATION; INTIMA-MEDIA THICKNESS; GLYCOPROTEIN IB-ALPHA; ANTI-GPVI ANTIBODIES; CONTROLLED PHASE-II; IN-VIVO; ANTIPLATELET THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1160/TH16-12-0911

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib alpha, and directed against GPVI, GPIIb/IIIa (integrin alpha(IIb)beta(3)), the thrombin receptor PAR-1, and the ADP receptor P2Y(12). The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.

引用

页码：1249 / 1257

页数：9

共 135 条

[1] Fibrin activates GPVI in human and mouse platelets [J].

Alshehri, Osama M. ;

Hughes, Craig E. ;

Montague, Samantha ;

Watson, Stephanie K. ;

Frampton, Jon ;

Bender, Markus ;

Watson, Steve P. .

BLOOD, 2015, 126 (13) :1601-1608

[2] Targeting GPVI as a novel antithrombotic strategy [J].

Andrews, Robert K. ;

Arthur, Jane F. ;

Gardiner, Elizabeth E. .

JOURNAL OF BLOOD MEDICINE, 2014, 5 :59-68

[3] Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 [J].

Armstrong, Duncan ;

Summers, Claire ;

Ewart, Lorna ;

Nylander, Sven ;

Sidaway, James E. ;

van Giezen, J. J. J. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2014, 19 (02) :209-219

[4] GPIIb/IIIa inhibitors: From bench to bedside and back to bench again [J].

Armstrong, Paul C. ;

Peter, Karlheinz .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) :808-814

[5] Platelet glycoprotein VI-related clinical defects [J].

Arthur, Jane F. ;

Dunkley, Scott ;

Andrews, Robert K. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) :363-372

[6] An Anti-von Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis [J].

Arzamendi, Dabit ;

Dandachli, Firas ;

Theoret, Jean-Francois ;

Ducrocq, Gregory ;

Chan, Mark ;

Mourad, Walid ;

Gilbert, James C. ;

Schaub, Robert G. ;

Tanguay, Jean-Francois ;

Merhi, Yahye .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2011, 17 (06) :E70-E78

[7] Adhesion of human and mouse platelets to collagen under shear: a unifying model [J].

Auger, JM ;

Kuijpers, MJE ;

Senis, YA ;

Watson, SP ;

Heemskerk, JWM .

FASEB JOURNAL, 2005, 19 (03) :825-+

[8] Targeting von Willebrand factor as a novel anti-platelet therapy; Application of ARC1779, an Anti-vWF aptamer, against thrombotic risk [J].

Bae, Ok-Nam .

ARCHIVES OF PHARMACAL RESEARCH, 2012, 35 (10) :1693-1699

[9] A mechanistic model for paradoxical platelet activation by ligand-mimetic αIIbβ3 (GPIIb/IIIa) antagonists [J].

Bassler, Nicole ;

Loeffler, Christoph ;

Mangin, Pierre ;

Yuan, Yuping ;

Schwarz, Meike ;

Hagemeyer, Christoph E. ;

Eisenhardt, Steffen U. ;

Ahrens, Ingo ;

Bode, Christoph ;

Jackson, Shaun P. ;

Peter, Karlheinz .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (03) :E9-E15

[10] Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study [J].

Becker, Richard C. ;

Moliterno, David J. ;

Jennings, Lisa K. ;

Pieper, Karen S. ;

Pei, Jinglan ;

Niederman, Alan ;

Ziada, Khaled M. ;

Berman, Gail ;

Strony, John ;

Joseph, Diane ;

Mahaffey, Kenneth W. ;

Van de Werf, Frans ;

Veltri, Enrico ;

Harrington, Robert A. .

LANCET, 2009, 373 (9667) :919-928

← 1 2 3 4 5 6 7 8 9 10 →